^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iboctadekin (SB-485232)

    i
    Associations
    News

    Trials

    Company:
    GSK
    Drug class:
    IL-18 stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma (NCT01768338)
    Phase 1
    Michael John Robertson
    Completed
    Last update posted :
    02/10/2023
    Initiation :
    02/01/2013
    Primary completion :
    03/01/2016
    Completion :
    08/03/2017
    CD20
    |
    Arzerra (ofatumumab) • iboctadekin (SB-485232)
    A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (NCT00500058)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    07/26/2017
    Initiation :
    07/31/2007
    Primary completion :
    03/04/2010
    Completion :
    03/04/2010
    CD20 • CD8 • IFNG • IL2RA • PTPRC • CD69 • FASLG • IL7R • NCAM1 • CD14 • CSF2 • ITGAM • FOXP3
    |
    Rituxan (rituximab) • iboctadekin (SB-485232)